A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954

Inclusion Criteria:

• Healthy males aged 30 to 65 years inclusive
• BMI of 18.0 to 35.0 kg/m2 inclusive
• Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion Criteria:

• Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients
• Presence or history of clinically significant allergy requiring treatment
• History of clinically significant cardiovascular, renal, hepatic, respiratory, dermatological or gastrointestinal disease, and neurological or psychiatric disorder
• History of cholecystectomy or gall stones
• History of GI surgery
• Acute diarrhoea or constipation in the 7 days before the predicted Day 1
• Participants who do not have suitable veins for multiple venepunctures/cannulation
• Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
• Evidence of renal impairment at screening
• Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1
• Participants who have previously been administered IMP in this study
• Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years
• Participants who have been administered IMP in an ADME study in the last 12 months
• Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
• Use of any prescribed or non-prescribed medication including antacids, gastric pH modifying agents, analgesics, herbal remedies, vitamins and minerals within 2 weeks of dosing
• Current smokers or known or suspected history of alcohol or drug abuse
• Excessive intake of caffeine-containing drinks or food